Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Cancer > Ovarian cancer > Flashcards

Ovarian cancer Flashcards

1
Q

STAGE I :

A

Limited to one or both ovaries

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

IA

A

Involves one ovary; capsule intact; no tumor on ovarian surface; no malignant cells in ascites
or peritoneal washings

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

IB

A

Involves both ovaries; capsule intact; no tumor on ovarian surface; negative washings

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

IC1

A

surgical spill

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

IC2

A

capsule ruptured or tumor on ovarian surface

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

IC3

A

malignant cells in ascetic fluid or positive washings

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

II

A

Tumor involves one or both ovaries with Pelvic extension( below pelvic brim) or Primary
Peritoneal cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

IIA

A

Extension or implants onto uterus or fallopian tube

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

IIB

A

Extension or implants onto other pelvic structures

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

III

A

tumor involves one/ both ovaries with cytological or histologically confirmed spread to
peritoneum outside of the pelvis and/or metastasis to the retroperitoneal LN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

IIIA

A

retroperitoneal LN only( CYTOLOGICALY /HISTOLOGICALY PROVED)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

IIIA1

A
  • Positive retroperitoneal LN
    IIIA1(i) – mets < equal to 10mm
    IIIA(ii)- mets > 10 mm
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

IIIA2

A

microscopic, extrapelvic (above pelvic brim ) , peritoneal involvement +/- positive retroperitoneal LN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

IIIB

A

Macroscopic extrapelvic peritoneal metastases beyond pelvis < or equal to 2 cm in size +/- positive
retroperitoneal LN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

IIIC

A

Peritoneal metastases beyond pelvis >2 cm or lymph node metastases LN (includes extension to capsule of
liver or spleen without paranchymal involvement of either organ)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

IV

A

Distant metastases – in the liver, or outside the peritoneal cavity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

IVA

A

plueral effusion with positive cytology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

IVB

A

hepatic/splenic parenchymal mets, metastasis to extra-abdominal organs
(involving inguinal LN and LN outside the abdominal cavity)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Fertility sparing surgery

A

STAGE Ia well-differentiated tumours ( Grade 1, possiblly grade 2 of
serous/mucinous and endometriod type):- U/L Salpingo-oopherectomy + Omentectomy+ peritoneal sampling
para-colic and sub-diaphragmatic b/l + LN assessement and removal.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

ADJUVANT CHEMOTHERAPY:-
 Stage Ia-Ib well-differentiated tumours ( Grade 1 and grade 2)

A

not offered adjuvant
chemotherapy

21
Q

Adjuvant chemo Stage Ia, Ib ( grade 3) and Stage Ic, clear cell subtypes

A

3- 6 cycles of single agent chemotherapy
every 3 weeks – CARBOPLATIN.

22
Q

Adjuvant chemo Stage II

A

carboplatin + paclitexal 6 cycles

23
Q

Interval debulking

A

ADVANCED 3C AND BEYOND
Neoadjuvant CT ( 3cycles) f/b Surgery f/b rest 3 cycles of CT. Both regimens are administered every three
weekly for six cycles

24
Q

Tissue biopsy

A

important for diagnosis
Use cytology together with CA-125/CEA >25:1 in patients if histology is not appropriate

25
Q

Platinum sensitive (PS)

A

progress with interval of > 6 months after completion of CT

26
Q

Platinum resistant

A

progress with interval of <6 months after completion of CT.

27
Q

Platinum Refractory

A

progress during or / within 4 weeks after completion of CT.

28
Q

Carboplatin hypersensitivity

A

desensitization attempted, or alternatively cisplatin

29
Q

Paclitexal neurotoxicity

A

Gemcitabine/ liposomal doxorubicin

30
Q

Bevacizumab

A

added to relapsed platinum-based CT and as maintenance afterwards increase
progress free survival, but S/E- HTN/ brain bleed

31
Q

PLATINUM RESISTANT AND PLATINUM REFRACTORY

A

Second line CT < 10% effective.
* No advantage of combination therapy as will only increase side effects.
* Single agent PLD / etoposide/ topotecan/ gemcitabine
* Addition of Bevacizumab is beneficial

32
Q

CLEAR HOBNAIL CELLS

A

Clear Cell Carcinoma

33
Q

Endometriod carcinoma of ovary

A

Second most common
 15% EOC
 Associated with endometriosis
 15% associated with endometrial cancer
 Squamous metaplasia is confirmatory
 Most frequently associated with endometriosis + hypercalcemis+ VTE

34
Q

ovarian cancer are likely to be hereditary

A

5-10 %

35
Q

BRCA1 and BRCA2.

A

These account for ≈ 40–50% of hereditary breast cancer-only families and 95% of families with both breast
and ovarian cancer.
 Autosomal dominant

36
Q

Cumulative risks for the development of breast/ovarian cancer.
 Normal population

A

breast 10%, ovarian 1.4%, endometrial 1.1%.

37
Q

Cumulative risks for the development of breast/ovarian cancer.BRCA 1

A

breast 65%, ovarian 20-50%.

38
Q

Cumulative risks for the development of breast/ovarian cancer.BRCA 2

A

breast 45%, ovarian 10-20% (male breast 6% and prostate cancer)

39
Q

Risk reducing surgery

A

BILATERAL SALPINGO-OOPHERECTOMY (RR BSO) DONE BY 35- 40 YEARS OR WHEN
CHILD BEARING IS COMPLETE.

40
Q

If RR surgery is refused in BRCA 1/2 people

A

TVS+ CA- 125 EVERY 6 MONTHS STARTING AT 35 YEARS OF AGE OR 5-10 YEARS EARLIER
THAN THE EARLIEST AGE OF FIRST DIAGNOSIS OF OVARIAN CANCER IN FAMILY.

41
Q

RR-BSO provides benefit of significantly reducing the risk of Breast Cancer by

A

30-75%

42
Q

RR Sx Reducing risk of Ovarian Cancer by

A

80-96%, increasing survival by 60-76%

43
Q

RR BSO is not completely protective carriers still have risk of developing Primary Peritoneal
Cancer

A

2%

44
Q

OCCULT RISK OF MALIGNANCY IN RR-BSO IS

A

4-20%.
 CHANCES ARE 4-8 % WHICH INCREASES TO 20% BY THE AGE OF 45 YEARS.
 SO TVS + CA- 125 BEFORE SURGERY ADVICED.

45
Q

)BRCA1 – OFFERED SURGERY ( RR BSO(BY

A

35 YEARS OR WHEN FAMILY COMPLETED.

46
Q

RR BSO BRCA 2

A

2-3% INCIDENCE FOR DECADE LATER THAN BRCA1 BY 50 YEARS AND AVERAGE
AGE IS SIMILAR TO GENERAL POPULATION THAT IS 60 YEARS- SO THESE PATIENT CAN DELAY
SURGERY, BUT THAN BY DELAYING SURGERY THEY WILL NOT BE BENEFFITED BY
REDUCTION IN RISK OF BREAST CANCER.

47
Q

OCCULT RISK OF MALIGNANCY IN RR-BSO IS

A

4-20%.

48
Q
A

Cancer (4 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions